[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News and Perspectives
May 18, 2011

Study Halted: No Benefit Seen From Antiretroviral Pill in Preventing HIV in Women

JAMA. 2011;305(19):1952. doi:10.1001/jama.2011.649

Researchers halted a trial in Africa designed to determine whether a daily dose of a pill containing 2 antiretroviral drugs would help prevent HIV infection in women after an interim assessment showed no evidence that the treatment was protective.

The study, called FEM-PrEP, is a randomized clinical trial of the safety and effectiveness of a daily pill containing emtricitabine and tenofovir (a combination sold under the name Truvada) in preventing HIV infection in women in Africa who are at higher risk of being exposed to HIV. It is one of several trials testing the use of antiretroviral drugs as a prevention strategy in at-risk populations.

First Page Preview View Large
First page PDF preview
First page PDF preview